HMNC Brain Health
Ani Damyanova has extensive work experience in the field of clinical operations. Ani most recently served as the Director of Clinical Operations at HMNC Brain Health since March 2022. Prior to that, they worked as a Clinical Trial Manager at 4SC AG from July 2021 to February 2022. Ani's career in clinical operations began at Bristol-Myers Squibb, where they served as a Clinical Site Manager from March 2013 to July 2021.
Ani Damyanova began their education journey in 2006 at Ludwig-Maximilians-Universität München, where they pursued Chemistry and Biochemistry without obtaining a degree. Ani continued their studies at the same institution from 2010 to 2012 and successfully earned a Master's degree in Biochemistry. In 2018, Ani Damyanova enrolled in FOM University of Applied Sciences for Economics and Management, where they focused on obtaining an MBA, concluding their education at this institution in 2020.
This person is not in any offices
HMNC Brain Health
HMNC Brain Health develops patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.Founded in 2010, the privately held biotech company combines the development of machine learning-enabled companion diagnostics with specifictherapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. The ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. HMNC Brain Health strives to reduce not only the immense individual burden but also the societal impact of these diseases.